STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- As per 29 August 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares, of which 356,000,049 are common shares and 1,412,788 are C-shares. The total number of votes is 356,141,327,8. The increase in the number of shares and votes results from issues of 1,412,788 class C shares. The class C shares have been issued for the purpose of ensuring fulfilment of commitments under the long-term incentive progr

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome[2] Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and

Johnson & Johnson on Thursday said it has halted clinical development of its FcRn blocker Imaavy (nipocalimab) in combination with UCB’s anti-TNFα therapy Cimzia (certolizumab pegol) for rheumatoid arthritis after a mid-stage proof-of-concept study showed underwhelming results.The Phase IIa DAISY study enrolled 103 adult patients with moderate to severe active rheumatoid arthritis for ≥3 months who were refractory to biologic disease-modifying anti-rheumatic drugs or anti-TNF agents. The partici

TAIPEI, Aug. 28, 2025 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for CAMCEVI ETM (leuprolide mesylate 21 mg, ready-to-use long-acting injectable (LAI) formulation administered every 3 months), as a treatment for advanced prostate cancer. "The approval of CAMCEVI ETM (21 mg) is a significant step toward our mission in improving the standard of care and the lives of pat

Second quarter (April-June 2025) Operating loss amounted to SEK -2,892,341 (-5,841,409). Loss for the period amounted to SEK -2,732,070 (-5,622,779). Cash flow from operating activities totaled SEK -5,991,211 (-7,733,270). Earnings per share before and after dilution totaled SEK -0.06 (-0.16). Period (April-June 2025) Operating loss amounted to SEK -10,961,745 (-11,274,831). Loss for the period amounted to SEK -10,745,532 (-10,992,456). Cash flow from operating activities totaled SEK -6,736,135

SHANGHAI, Aug. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2025 along with a corporate update. "In the first half of 2025, Everest Medicines accelerated its transformation into a leading global biopharmaceutical company by deepening our 'dual-engine' strategy," commen

SOUTHLAKE, Texas, Aug. 28, 2025 /PRNewswire/ -- Hopkins Dermatology is pleased to welcome dermatologist Dr. Douglas Farris to its Southlake location. With over 25 years of experience and a strong reputation for personalized, compassionate care, Dr. Farris brings advanced clinical expertise across medical, nutritional, and functional dermatology. Since entering private practice in 1999, Dr. Farris has focused on building trusted relationships with his patients—listening carefully to their concern

Vigna Law Group alleges patient with bedsore was denied standard care, resulting in serious complications Our client required a Clinitron bed for pressure relief, timely surgical debridement of the sacral bedsore, nutritional support, treatment with IV antibiotics, and flap closure of pressure wounds.” — Greg Vigna, MD, JD LOS ANGELES, CA, UNITED STATES, August 28, 2025 / EINPresswire.com / -- “It is our position that The Methodist Hospital did not take adequate steps to prevent our client from

AVENTURA, Fla., Aug. 28, 2025 /PRNewswire/ -- RAD Technology Medical Systems (RAD) is proud to announce the installation of its RAD Temp at Titus Regional Medical Center (TRMC) in Mt. Pleasant, Texas. The temporary radiotherapy facility, installed adjacent to CancerCARE at Titus—Patty & Bo Pilgrim Cancer Center, ensures uninterrupted services while TRMC upgrades its current vault and linear accelerator to provide greater precision and improved treatment options. Continue Reading The RAD Temp, a

RX-O2 Hyperbaric Clinics celebrates 20 years in the Valley with state-of-the-art multiplace hyperbaric chambers, expanding safe and affordable HBOT access. We are ensuring not just access to hyperbaric oxygen therapy but access to therapy that is safe, ethical, and effective, Patients deserve more than availability; they deserve excellence.” — Dr. Marvin Borsand SCOTTSDALE, AZ, UNITED STATES, August 28, 2025 / EINPresswire.com / -- RX-O2 Hyperbaric Clinics , a pioneer in hyperbaric oxygen therap